Results 191 to 200 of about 32,341 (221)
Some of the next articles are maybe not open access.
2011
Neurofibromatosis type 2 (NF2) is an autosomal-dominant inherited tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. Affected individuals develop schwannomas characteristically affecting both vestibular nerves leading to hearing loss and eventual deafness.
Evans, GR, Lloyd, SK, Ramsden, RT
+8 more sources
Neurofibromatosis type 2 (NF2) is an autosomal-dominant inherited tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. Affected individuals develop schwannomas characteristically affecting both vestibular nerves leading to hearing loss and eventual deafness.
Evans, GR, Lloyd, SK, Ramsden, RT
+8 more sources
Acta Otorrinolaringológica Española, 2010
Type 2 neurofibromatosis (NF2) is an invalidating, inherited, dominant, autosomal disease. It is commonly confused with type 1 neurofibromatosis, although the two disorders are different. All subjects who inherit a mutated NF2 gene will develop the disease, which is characterised by the growth of schwannomas, generally affecting the vestibular nerve ...
Marta, Pérez-Grau +5 more
openaire +2 more sources
Type 2 neurofibromatosis (NF2) is an invalidating, inherited, dominant, autosomal disease. It is commonly confused with type 1 neurofibromatosis, although the two disorders are different. All subjects who inherit a mutated NF2 gene will develop the disease, which is characterised by the growth of schwannomas, generally affecting the vestibular nerve ...
Marta, Pérez-Grau +5 more
openaire +2 more sources
2004
Type 2 neurofibromatosis (NF2) is an autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene NF2 on chromosome 22. Around 1 in 33000 people are born with an NF2 mutation although more than one-third of the 60% of de novo cases are not conceived with the mutation but this develops later in embryogenesis (mosaics).
openaire +2 more sources
Type 2 neurofibromatosis (NF2) is an autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene NF2 on chromosome 22. Around 1 in 33000 people are born with an NF2 mutation although more than one-third of the 60% of de novo cases are not conceived with the mutation but this develops later in embryogenesis (mosaics).
openaire +2 more sources
Journal of the American Academy of Dermatology, 2001
K S, Caldemeyer, G W, Mirowski
openaire +2 more sources
K S, Caldemeyer, G W, Mirowski
openaire +2 more sources
An overview of real‐world data sources for oncology and considerations for research
Ca-A Cancer Journal for Clinicians, 2022Lynne Penberthy +2 more
exaly
Health insurance status and cancer stage at diagnosis and survival in the United States
Ca-A Cancer Journal for Clinicians, 2022Jingxuan Zhao +2 more
exaly
An overview of precision oncology basket and umbrella trials for clinicians
Ca-A Cancer Journal for Clinicians, 2020Kristian Thorlund, Edward J Mills
exaly
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
Ca-A Cancer Journal for Clinicians, 2018David A Mahvi +2 more
exaly